Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “OSTEOPOROSIS”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 901 records · Page 50Linked to original sources

Older women with fractures: patients falling through the cracks of guideline-recommended osteoporosis screening and treatment.

BACKGROUND: Many older patients with fractures are not managed in accordance with evidence-based clinical guidelines for osteoporosis. Guidelines recommend that these patients receive treatment for clinically apparent osteoporosis or have bone mineral density measurements followed by treatment when appropriate. This cohort study was conducted to further characterize the gap between guidelines and actual practice with regard to bone mineral density measurement and treatment of older women after a fracture. Our purpose was to aid in the design of more effective future interventions. METHODS: We identified female members of a not-for-profit group-model health maintenance organization who were fifty years of age or older and who had a diagnosis of a new fracture as defined in the study. We used administrative databases and the clinical electronic medical records to obtain data on demographics, diagnoses, drugs dispensed by the pharmacy, and the measurement of bone mineral density. RESULTS: The study population included 3812 women with an average age of 71.3 years. Fewer than 12% of the women had a diagnosis of osteoporosis prior to the index fracture; 10.7% had an increased risk for secondary osteoporosis and 38.8%, for falls because of a diagnosis or medication. It was found that 46.4% of the study population had been managed as specified by clinical guidelines. The patients who had been managed as specified by the guidelines were younger and less likely to have the risk factor of a weight of <127 lb (58 kg), a hip fracture, or a wrist fracture. They were also more likely to be taking steroids on a chronic basis and to have had a vertebral fracture. The percentage of women who had measurement of bone mineral density increased during the study period, from 1.3% in 1998 to 10.2% in 2001. Of the patients receiving treatment for osteoporosis, 73.6% adhered to the treatment regimen. CONCLUSIONS: Adherence to guidelines for evaluation and treatment for osteoporosis after a patient sustained a fracture did not improve between 1998 and 2001 despite the promulgation of evidence-based guidelines. Methods to enhance education and facilitate processes of care will be necessary to reduce this gap. It may be fruitful to target high-risk subgroups for tailored interventions for prevention of refracture.

Absorptiometry, Photon↗

[The influence of the different components of nourishing kidney herbs on osteoporosis rats].

OBJECTIVE: To observe the influent of the different components of nourishing kidney herbs on the main items of bone metabolism in osteoporosis rats induced with Dexamethasona(DXM). METHOD: Models of three-month old SD female rats with osteoporosis here made by being fed with low calcium diet (containing calcium 0.2%) and distilled water, and injected with DXM 0.1 mg/100 g weight intramuscularly, twice a week. Then the osteoporosis rats were treated with different components of nourishing kidney herbs, and the change of calcium, phosphate, alkaline phosphatase(ALP), calcitonin(CT), PTH, CT/PTH, estrogen(E2), testosterone(T), T/E2 and bone section and bone quantitative morphology in these osteoporosis rats were observed. RESULT: The total components of nourishing kidney herbs could improve the general condition of osteoporosis rats, decrease PTH, increase CT, estrogen, testosterone, CT/PTH and T/E2. The total components of nourishing kidney herbs could improve osteoporotic state, promote bone formation, and inhibite bone resorption. But no effect of the A, B, C, D components of nourishing kidney herbs on the main items of bone metabolism in osteoporosis rats induced with DXM was found. CONCLUSION: It is possible that the purification and separation of these herbs weaken or destroy the integrative effect of nourishing kidney herbs or destroy effective components of nourishing kidney herbs during the process of purification and separation.

Animals↗

Patient education--the forgotten link in managing osteoporosis.

BACKGROUND: Osteoporosis and bone fractures are common, yet osteoporosis is under diagnosed in Australian settings. Osteoporosis can now be reliably diagnosed, and safely and effectively treated, but patient education strategies are under utilised. OBJECTIVE: This article discusses the role of education in osteoporosis risk reduction and management. DISCUSSION: Osteoporosis education initiatives such as the Osteoporosis Prevention and Self Management Course can increase knowledge, self efficacy and health related behaviours such as calcium intake and exercise over the short to medium term.

Humans↗

Osteoporosis: a review.

Osteoporosis is the most common metabolic bone disorder and remains an increasingly significant problem, affecting 200 million individuals worldwide. Osteoporosis often is undertreated and underrecognized, in part because it is a clinically silent disease until it manifests in the form of fracture. Sufficient recognition of the disease and its appropriate medical and nonmedical treatment are essential. Treatments including calcium and vitamin D, the bisphosphonates, estrogen, selective estrogen receptor modulators, calcitonin, parathyroid hormone, balance and exercise training programs, and the minimally invasive spine procedures vertebroplasty and kyphoplasty comprise a comprehensive multidisciplinary approach in the treatment of osteoporosis. The data suggest that medical treatment of osteoporosis is increasing each year as physician awareness is heightened. Nonmedical treatment of osteoporosis complements the appropriate pharmacologic treatment, and these treatments should be used together to maximize outcomes for patients with osteoporosis. Fracture data for the intravenous biphosphonates and the long-term effects of the minimally-invasive spine procedures vertebroplasty and kyphoplasty have yet to be reported in the literature, but the effects on bone mineral density, and short-term results of these procedures, respectively, have been promising.

Biomechanical Phenomena↗

Osteoporosis: a disease in men.

Osteoporosis, a metabolic bone disease characterized by low bone mass, microarchitectural deterioration of bone tissue, and increased susceptibility to fracture, now is recognized to be a disease of men and women. Based on bone mineral density measurements established by the World Health Organization, approximately 2 million men in the United States currently are affected. Information about the pathogenesis, diagnosis, and treatment of osteoporosis in men is accumulating. Estrogen now is known to be necessary for normal skeletal maturation and for maintenance of adult bone mass in men. As we will discuss, the age-related decline in bone mineral density in men seems to result from an age-related decline in the levels of bioavailable estrogen. Osteoporosis candidate genes have been discovered, and their polymorphisms may predispose men to a weakened, osteoporotic phenotype. Determining a bone mineral density standard to diagnose men with osteoporosis has proven challenging, often leaving diagnosis until a fragility fracture has occurred. General prevention strategies for osteoporosis in men are targeted at men most likely to sustain a fragility fracture. Specific medical therapies for osteoporosis in men, including bisphosphonates and intermittent parathyroid hormone, are proving promising.

Aging↗

Effect of intravenous calcium load on the serum calcium level in postmenopausal osteoporosis (a study of the pathogenesis, and diagnostic use of the test).

Analysis of calcium tolerance in suggested to represent a valuable diagnostic aid in osteoporosis, particulary in the menopause. The serum calcium level was found to exceed 11.0 mg/dl 60 min after the intravenous injection of 3.6 mg per kg body weight of Ca++ in all patients with osteoporosis, while the level was normal at that point of time in every subject without osteoporosis, including patients with bone disease other than osteoporosis. Administration of norandrosterone decanoate or dehydroepinandrosterone to patients with menopausal osteoporosis resulted in normalization of the post-load hypercalcaemia. Calcium tolerance of menopausal patients without osteoporosis was not affected by dehydroepiandrosterone.

Calcium↗

Health-economic comparison of three recommended drugs for the treatment of osteoporosis.

Osteoporosis is a large and growing disease with significant health consequences. Based on an evaluation of clinical evidence, the German osteology umbrella organization DVO (Dachverband Osteologie deutschsprachiger wissenschaftlicher Fachgesellschaften) published guidelines in March 2003 for the diagnosis and treatment of osteoporosis. For prevention of fractures in women with postmenopausal and senile osteoporosis, these guidelines recommend three treatment options as first-line therapy: risedronate, alendronate and raloxifene. No evidence is currently available for the reduction of hip fractures by raloxifene. Only risedronate and alendronate, therefore, are recommended for prevention of hip fractures. Information on the cost-effectiveness of preventing and treating osteoporosis may support decision makers in more efficient allocation of resources. Accordingly, the objective of this study is the comparative assessment of the cost-effectiveness of risedronate, alendronate and raloxifene for patient populations in Germany at high risk of osteoporotic fracture due to low bone mineral density (BMD) (i.e., T-score < -2.5) and resulting from a history of at least one previous vertebral fracture, as compared to osteoporotic patients with no treatment. Target variables for the economic comparison are costs per hip fracture avoided and costs per quality-adjusted life year (QALY) gained. Hip fractures are the most costly and best-documented complication of osteoporosis. A cost-effectiveness analysis was therefore conducted, using as criteria for evaluating intervention the incremental cost per hip fracture avoided and the cost per QALY gained. We used a fracture-incidence-based Markov model of osteoporosis, with analysis of patients' transition across outcome states over time (e.g., fracture, healthy, dead). Base-case analysis was conducted on a cohort of 1,000 women aged 70 with low spine BMD and prevalent vertebral fracture, over 3 years of treatment with risedronate, alendronate or raloxifene, and with application of a 10-year analytic time horizon. Model inputs included hip and vertebral fracture incidence rates; relative risk of fracture given low BMD and prevalent vertebral fracture, fracture cost, treatment prices/day (risedronate: 35 mg, 1.76 euro; alendronate: 70 mg, 1.82 euro; raloxifene: 60 mg, 1.82 euro); health utility; and efficacy in terms of relative-risk reduction of fracture of the hip (60% risedronate; 51% alendronate; not significant raloxifene) and vertebrae (49% risedronate; 47% alendronate; 30% raloxifene). A 5% discount rate was applied to cost and outcomes. In the base case, treatment with risedronate reduces costs from the social insurance perspective with respect to both endpoints: i.e., costs per averted hip fracture and QALY. Over the 3-year treatment period and 10-year observation, furthermore, risedronate proved superior to alendronate and raloxifene (i.e., risedronate was less expensive and more effective). From the perspective of statutory health insurance, the cost per averted hip fracture is 37,348 euro for risedronate and 48,349 euro for alendronate (costs for raloxifene were not calculated due to a nonsignificant effect on prevention of hip fractures); and cost per QALY gained is 32,092 euro for risedronate, in comparison to patients in Germany with no therapy (alendronate 41,302 euro; raloxifene 1,247,119 euro). This cost-effectiveness analysis gives evidence that bisphosphonates are cost effective. Under consideration of current prices and the published clinical evidence, risedronate dominates the comparison of DVO-recommended drugs.

Aged↗

Preventing osteoporosis in every day life.

Osteoporosis is a condition characterized by low bone mineral density, microarchitectural deterioration of bone tissue, and a consequent increase in fracture risk. The public health impact of osteoporosis stems from its association with fractures of the hip, spine and forearm. Between 10 and 20 percent of hip fracture patients die within a year of the event, and among those who survive, almost two-thirds remain disabled. The medical costs of osteoporosis and its attendant fractures have been placed at 5.2 billion dollars each year in the US and 615 million pound sterling each year in the UK. In Asia, osteoporosis is rapidly becoming a major public health problem with an increasing incidence of hip fracture and a rapidly aging population. By the year 2050, more than half of the hip fracture around the world would occur in Asia, with the total number approaching 3.2 million. Osteoporosis can be attributed to both genetic factors and environmental factors. While it is difficult to modify genes, much can be done to prevent osteoporosis in our every day life. These are discussed below.

Accidental Falls↗

[Present condition and future direction of osteoporosis in Japan].

The purpose of this special issue is to clarify the problems in the prevention, the treatment and the care of osteoporotic patients in Japan. Herein, we presented the accumulating evidence about the epidemiology, the prevention, the screening and the therapy of osteoporosis. We also introduced the countermeasures for osteoporosis through the life and the medical financial studies etc. The government, the medical societies and the foundations support the studies for osteoporosis and have proposed the guidelines for osteoporosis. We overviewed the prospective of osteoporosis and fracture prevention. For the establishment of healthy longevity society, we should continue the effort to solve the problems in osteoporosis in Japan.

Humans↗

[The frequency of osteoporosis diagnosis depending on the site and method of bone examination].

The aim of the study has been to evaluate how often osteoporosis is diagnosed in DEXA examination of the spinal column and proximal epiphysis of the femoral bone as well as in ultrasonography of the heel in a population group. The study comprised 536 post-menopausal women aged 54.36+/-10.91 years. A fracture in history was reported by 158 patients, including 57 fractures characteristic of osteoporosis (spinal column, forearm, proximal epiphysis of the femoral bone). Osteoporosis was diagnosed in 0.4% patients in the greater trochanter, in 1.5% in the neck of femur, in 7.8% in the Ward triangle, in 12.8% in the L1-L4 segment of the spine, and in as many as 36.2% in the calcaneal bone. Here, no abnormalities were found only in 14.2% of the patients. The frequency of positive osteoporosis diagnosis did not differ significantly between the groups with and without fractures in history. There was a correlation found between measurements results of the spine and the Ward triangle, and between the neck of femur and the greater trochanter. In the remaining DEXA measurements, the statistics values were a little beyond the critical ones. On the other hand, ultrasonographic diagnosis of osteoporosis in the heel did not correlate absolutely with those of DEXA. T-score in each measurement correlated with each other at r from 0.453 to 0.905, with the highest values when in DEXA. Comparing T-score in sonography of the heel with those of DEXA suggests that they have been overrated by one standard deviation. In conclusion, the frequency of osteoporosis diagnosis has been found to differ significantly depending on the method and site of measurement. The measurement discrepancy in various sites is substantial despite a high correlation between them. The paper's results suggest that it is necessary to work out other diagnostic criteria for the ultrasonographic examination of the heel.

Absorptiometry, Photon↗

[Idiopathic and secondary osteoporosis in childhood].

Osteoporosis is a common disease characterized by reduced bone mass, with a consequent increase in bone fragility and susceptibility to fracture risk. Bone mineral density (BMD) measurement is used to make the diagnosis of osteoporosis prior to incident fracture, and to predict fracture risk. BMD is determined by the peak bone mass achieved, and the rate and timing of subsequent bone loss. Dual-energy X-ray absorptiometry (DEXA) is the most popular and effective method utilized for osteoporosis screening. Bone disease is a side effect of concern regarding chronic glucocorticoid (GC) administration. Most GC-treated patients exhibit a process of bone loss, frequently leading to osteoporosis, with increased fracture risk, especially in spinal vertebrae. Osteogenesis imperfecta is an inherited and generalized connective tissue disorder characterized mainly by bone fragility. Idiopathic osteoporosis of childhood or adolescence without blue sclerae and other stigmata of osteogenesis imperfecta is occasionally observed and sometimes more than one sib is affected. Beta-thalassemia major is associated with significant bone disease. The etiology of the bone disease is still debatable, many factors can adversely affect bone accretion in thalassemic patients. These include delayed puberty, bone marrow expansion, the deleterious effects of desferrioxamine, iron overload and genetic factors. Current treatment alternatives of osteoporosis include bisphosphonates, calcitonin, and selective estrogen receptor modulators.

Absorptiometry, Photon↗

Osteoporosis in liver cirrhosis.

BACKGROUND: Osteoporosis is still an underestimated complication of liver cirrhosis (LC). AIM. To study the prevalence of osteoporosis and osteopenia in patients with LC and to identify the principal risk factors associated. MATERIAL AND METHODS: The prevalence of osteoporosis and osteopenia was studied in 150 patients with alcoholic or viral LC who were admitted to the Institute of Gastroenterology and Hepatology, Iasi in 2003. Osteoporosis was diagnosed by measuring their bone density using dual energy X-ray absorptiometry (DXA). Patients with liver disease due to multiple aetiologies or with other liver conditions (primary biliary cirrhosis, autoimmune or metabolic causes, etc.) as well post menopausal women were excluded from the study. The variables taken into consideration were: gender, nutritional status (body mass index - BMI), etiology of liver disease, presence of cholestasis, severity and duration of disease. RESULTS: Fifty-seven patients with LC (38%) were found to have osteoporosis or osteopenia. There was a statistically significant correlation between the presence of bone changes and a BMI of <20 kg/m2, cholestasis, Child class C and long duration of disease (>10 years). During the study period, despite the relatively high rate of bone metabolism abnormalities, there were no pathological fractures in the patients group. CONCLUSIONS: Osteoporosis has a raised prevalence in patients with LC. It is important to be diagnosed and treated early, especially when risk factors such as malnutrition, cholestasis and a severe liver disease are present for a long period of time.

Absorptiometry, Photon↗

Osteoporosis in postmenopausal women. Therapy options across a wide range of risk for fracture.

Osteoporosis is a highly prevalent skeletal disorder characterized by compromised bone strength predisposing individuals to an increased risk of fractures. Fractures related to osteoporosis are frequently associated with chronic pain and decreased quality of life, as well as significant morbidity and mortality. Postmenopausal women are at higher risk for developing osteoporosis and osteoporosis-related fractures. Osteoporosis fractures are commonly asymptomatic, necessitating a need for proactive screening, diagnostic testing, and more importantly, therapeutic intervention that will rapidly reduce the risk of fractures in at-risk patients. Current pharmacologic prevention and treatment options for osteoporosis include antiresorptive therapies (alendronate, risedronate, ibandronate, raloxifene, hormone therapy, and calcitonin) and the anabolic agent teriparatide.

Aged↗

[Multi-slice spiral CT using spinal structure assessment in elderly patients with osteoporosis].

OBJECTIVE: To explore the clinical value of 64-slice spiral CT for spinal structure assessment in elderly patients with osteoporosis. METHODS: The computed radiography (CR) films and 64-slice spiral CT isotropic scanning images of 40 patients who had been diagnosed as osteoporosis by dual-energy X-ray absorptiometry (DXA) were retrospectively analyzed. The patients were divided into two groups according to their T-scores by DXA: group A (T-score was -1.0 - (-2.5)); and B group (T-score was below -2.5). RESULTS: The diagnostic results of axial CT images combined with multi-planar reconstruction (MPR) was negatively correlated with the measurement results of DXA in the diagnosis of spinal osteoporosis, and such correlation was higher in group B than in group A. Compared with CR films, axial CT images combining with MPR showed superior effectiveness in the diagnosis of osteoporosis. CONCLUSIONS: 64-slice spiral CT is better than CR in diagnosis of osteoporosis. CT-MPR and 3D reconstruction not only can be used to diagnose osteoporosis early, but also to observe the changes of skeleton's shape and overall structure.

Aged↗

Prevalence of osteoporosis in Thai men.

BACKGROUND: Osteoporosis is a growing health problem not only in women but also in men. However, there is a scarcity of epidemiologic data to study osteoporosis in Thai men. OBJECTIVES: To examine the bone mineral density (BMD) and to determine the prevalence of osteoporosis in Thai men. MATERIAL AND METHOD: A total of 412 men (159 from Bangkok and 253 from Khon Kaen, respectively) averaging 51 +/- 16 years of age, were measured for BMD at the femoral neck and lumbar spine by dual energy X-ray absorptiometry (LUNAR Corporation, WI, USA). RESULTS: The peak BMD was observed in men 20-29 years of age at both the femoral neck (mean +/- SD, 1.10 +/- 0.15 g/cm2) and lumbar spine (mean +/- SD, 1.17 +/- 0.13 g/cm2). The prevalence of osteoporosis in the entire group of subjects was 12.6, 4.6 and 3.9 per cent at the femoral neck, lumbar spine and both sites, respectively. The prevalence of osteoporosis increased with advancing age and was significantly higher at the femoral neck in urban men than rural men (18.2 vs 9.2 per cent, p < 0.05) but comparable at the lumbar spine (5.0 vs 4.3 per cent, p = 0.81). The correlation between femoral neck and lumbar spine BMDs was 0.53 (p < 0.001). In univariate analysis, increased age, lower weight and lesser height were each associated with lower femoral neck BMD, whereas only lower weight and lesser height were associated with lower lumbar spine BMD. However, when the three factors were entered simultaneously, only increased age and lower weight were significantly associated with lower femoral neck BMD and only lower weight had a significant association with lower lumbar spine BMD. CONCLUSION: The present study demonstrated descriptive BMD data, normal BMD reference values for diagnosis and reported the prevalence of osteoporosis in Thai men.

Absorptiometry, Photon↗

The prevalence and risk factors of osteoporosis in Thai renal-transplant patients.

OBJECTIVES: To determine the prevalence and risk factors of osteoporosis after renal transplantation in Thai patients. MATERIAL AND METHOD: A single-center cross-sectional study of bone mineral density was conducted in 102 Thai renal allograft recipients. Correlations were made between the clinical parameters and the occurrences of osteoporosis. RESULTS: The prevalence of osteoporosis was 24.5%, 9.8% and 26.4% at lumbar vertebrae, hip region, and any sites, respectively. Binary logistic regression analysis revealed that cumulative dosage of steroids was significantly correlated with osteoporosis of the lumbar spine (p = 0.023, adjusted OR = 1.005), while body mass index (p = 0.005, adjusted OR = 0.738) and age (p = 0.052, adjusted OR = 1.077) were correlated with osteoporosis of the hip region. CONCLUSION: Osteoporosis is common in Thai renal allograft recipients, particularly of the lumbar vertebrae. Cumulative dosage of steroids is the most important risk factor of low BMD of the lumbar vertebrae.

Bone Density↗

Pharmacogenomics of osteoporosis: opportunities and challenges.

The genetics of osteoporosis can be considered in two broad areas: disease susceptibility and drug activity. While the former has been studied, the latter is still largely untouched. Pharmacogenomics is the utilization of genetic information to predict outcome of drug treatment, with respect to both beneficial and adverse effects. The pharmacotherapy of osteoporosis is characterized by variability in therapeutic response with limited prediction of response on a patient-by-patient basis. This is particularly problematic in a clinical situation where therapy is typically required for several years before outcomes can be evaluated for an individual. Thus, the emerging field of pharmacogenomics holds great potential for refining and optimising pharmacological treatment of osteoporosis. Key components for future development of the pharmacogenomics of osteoporosis should include improved understanding of mechanisms of drug action, identification of candidate genes and their variants and expansion of clinical trials to include genetic profiling. This approach could provide clinicians and scientists with powerful tools to dissect novel molecular pathways involved in osteoporosis and to identify new drug targets. The iterative combination of innovative genomics with classical endocrinological approaches in osteoporosis research can be examined as a model of biological research and innovate therapeutical approaches in a continuing interaction between clinical science and basic research.

Animals↗

Importance of early diagnosis and treatment of osteoporosis to prevent fractures.

Osteoporosis affects about 10 million individuals in the United States, a number that is expected to increase substantially in coming decades as the elderly population burgeons. The chief debilitating consequence of osteoporosis, fracture, will affect about half the women and a third of the men in their lifetime, posing a daunting challenge to managed healthcare systems in terms of delivering optimal care and restraining cost. By encouraging optimal postfracture follow-up care and identifying those members at higher risk for fracture and in need of prompt treatment, managed care organizations can enhance the cost-effective management of osteoporosis, dampening downstream costs. This manuscript reviews the pathophysiology of osteoporosis, examines issues related to the diagnosis of osteoporosis, especially the role of bone mineral density measurement, and focuses on the impact of various treatment options in reducing fracture risk. Early assessment and treatment emerge as medically prudent steps in reducing the risk for osteoporosis-related fracture.

Aged↗